Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Study of Glaucoma or Ocular Hypertension in Patients Within the United States

ClinicalTrials.gov ID: NCT00800267

Public ClinicalTrials.gov record NCT00800267. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 6-month, Randomized, Double-masked Comparison of Fixed Combination of Latanoprost and Timolol With the Individual Components, Continuing Into a 6-month Open Label Safety Study of Fixed Combination in Patients With Glaucoma or Ocular Hypertension. A Multicenter Study in the United States

Study identification

NCT ID
NCT00800267
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
418 participants

Conditions and interventions

Interventions

  • latanoprost 0.005% Drug
  • fixed combination latanoprost-timolol Drug
  • timolol 0.5% Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 1997
Primary completion
May 31, 1999
Completion
May 31, 1999
Last update posted
Feb 17, 2021

1997 – 1999

United States locations

U.S. sites
53
U.S. states
23
U.S. cities
42
Facility City State ZIP Site status
Pfizer Investigational Site Anaheim California 92801
Pfizer Investigational Site Anaheim California 92807
Pfizer Investigational Site Sacramento California 95819
Pfizer Investigational Site Sacramento California 95823
Pfizer Investigational Site San Francisco California 94115
Pfizer Investigational Site Boulder Colorado 80304-3573
Pfizer Investigational Site Denver Colorado 80210
Pfizer Investigational Site Largo Florida 34640
Pfizer Investigational Site Tampa Florida 33613
Pfizer Investigational Site Atlanta Georgia 30322
Pfizer Investigational Site Atlanta Georgia 30342
Pfizer Investigational Site Atlanta Georgia 30349
Pfizer Investigational Site East Point Georgia 30223
Pfizer Investigational Site Griffin Georgia 30223
Pfizer Investigational Site Morrow Georgia 30260
Pfizer Investigational Site Chicago Illinois 60612
Pfizer Investigational Site Wheaton Illinois 60187
Pfizer Investigational Site Elkhart Indiana 46515
Pfizer Investigational Site Mishawaka Indiana 46545
Pfizer Investigational Site South Bend Indiana 46601
Pfizer Investigational Site South Bend Indiana 46617
Pfizer Investigational Site Iowa City Iowa 52245
Pfizer Investigational Site Louisville Kentucky 40207
Pfizer Investigational Site Baltimore Maryland 21201
Pfizer Investigational Site Owings Mills Maryland 21117
Pfizer Investigational Site Boston Massachusetts 02111
Pfizer Investigational Site Golden Valley Minnesota 55422
Pfizer Investigational Site Minneapolis Minnesota 55421
Pfizer Investigational Site Kansas City Missouri 64111
Pfizer Investigational Site Kansas City Missouri 64114
Pfizer Investigational Site Warrensburg Missouri 64093
Pfizer Investigational Site Concord New Hampshire 03301
Pfizer Investigational Site South Plainfield New Jersey 07080
Pfizer Investigational Site Charlotte North Carolina 28204
Pfizer Investigational Site Charlotte North Carolina 28210
Pfizer Investigational Site Charlotte North Carolina 28260
Pfizer Investigational Site Matthews North Carolina 28105
Pfizer Investigational Site Monroe North Carolina 28112
Pfizer Investigational Site Portland Oregon 97201
Pfizer Investigational Site Portland Oregon 97210
Pfizer Investigational Site Wyomissing Pennsylvania 19610
Pfizer Investigational Site Charleston South Carolina 29412
Pfizer Investigational Site Mt. Pleasant South Carolina 29464-3245
Pfizer Investigational Site Memphis Tennessee 38119
Pfizer Investigational Site Austin Texas 78731-4941
Pfizer Investigational Site Galveston Texas 77555-1141
Pfizer Investigational Site Houston Texas 77030
Pfizer Investigational Site Charlottesville Virginia
Pfizer Investigational Site Richmond Virginia 23219
Pfizer Investigational Site Richmond Virginia 23235
Pfizer Investigational Site Tacoma Washington 98431
Pfizer Investigational Site Madison Wisconsin 53705
Pfizer Investigational Site Madison Wisconsin 53715

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00800267, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 17, 2021 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00800267 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →